FUNDAMENTALS · Fundamentals · US Healthcare

Septerna (SEPN) Fundamentals 2026 — Revenue Analysis | SniperIQ

Septerna (SEPN) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.5B, trading at
3.35 on the NASDAQ. This SniperIQ fundamentals page covers Septerna's valuation, profitability (net margin -49.9%), revenue ($46M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.5B
Net Margin-49.9%
Revenue (FY25)$46M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Septerna's market cap?

Septerna (SEPN) has a market capitalization of approximately

.5B, trading at
3.35 on the NASDAQ. Market cap moves with the live share price.

What is Septerna's P/E ratio?

Septerna's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Septerna?

Septerna runs a net profit margin of -49.9%, a gross margin of 99.4%, and an operating margin of -77.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Septerna generate?

Septerna reported revenue of $46M for fiscal year 2025, with net income of -$49M and earnings per share (EPS) of -1.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Septerna pay a dividend?

Septerna does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Septerna financially healthy?

Septerna carries a debt-to-equity ratio of 0.06x and a current ratio of 4.71x, with a market beta of 3.50. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Septerna a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Septerna (SEPN) the key facts are: market cap

.5B, revenue $46M, 52-week range 10.616-38.04. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Septerna's full fundamentals live

Get Septerna's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Bicara Therapeutics Inc. Common Stock (BCAX) fundamentals · Dawnrays Pharmaceutical (Holdings) (2348) fundamentals · PW Medtech Group (1358) fundamentals · Rapport Therapeutics, Inc. Common Stock (RAPP) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons